Trends in blood transfusion among hospitalized children with sickle cell disease

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1753-1758

  Raphael, Jean L ^a   Oyeku, Suzette O ^b   Kowalkowski, Marc A ^a   Mueller, Brigitta U ^a   Ellison, Angela M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Epidemiology; Health care utilization; Outcomes research; Sickle cell disease

Indexed keywords

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BLOOD TRANSFUSION; CHILD; CROSS-SECTIONAL STUDY; ETHNICITY; EUROPEAN AMERICAN; FEMALE; GENDER; GEOGRAPHY; HEALTH INSURANCE; HISPANIC; HOSPITAL BED CAPACITY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE; RURAL AREA; SCHOOL CHILD; SICKLE CELL ANEMIA; TIME; TREATMENT OUTCOME; TREND STUDY; URBAN AREA;

EPIDEMIOLOGY; HEALTH CARE UTILIZATION; OUTCOMES RESEARCH; SICKLE CELL DISEASE;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INPATIENTS; MALE;

EID: 84883778809     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24630     Document Type: Article

References (39)

1. The Management of Sickle Cell Disease: National Institutes of Health: National Heart, Lung, and Blood Institute; 2002. Report. NIH Publication No. 02-2117.
2. Frank NC, Allison SM, Cant MEC. Sickle cell disease. In: Brown RT, editor. Cognitive aspects of chronic illness in children. New York: Guilford Press; 1999. pp 172-189.
3. Smith JA. The natural history of sickle cell disease. Ann N Y Acad Sci 1989; 565:104-108.
4. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663-1672.
5. Josephson CD, Su LL, Hillyer KL, et al. Transfusion in the patient with sickle cell disease: A critical review of the literature and transfusion guidelines. Transfus Med Rev 2007; 21:118-133.
6. Vichinsky EP, Ohene-Frempong K, Thein SL, et al. Transfusion and chelation practices in sickle cell disease: A regional perspective. Pediatr Hematol Oncol 2011; 28:124-133.
7. Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer 2012; 59:358-364.
8. Reed W, Vichinsky EP. New considerations in the treatment of sickle cell disease. Annu Rev Med 1998; 49:461-474.
9. Nifong TP, Domen RE. Oxygen saturation and hemoglobin A content in patients with sickle cell disease undergoing erythrocytapheresis. Ther Apher 2002; 6:390-393.
10. Thurston GB, Henderson NM, Jeng M. Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood. Clin Hemorheol Microcirc 2004; 30:61-75.
11. Rogers ZR, Review: Clinical transfusion management in sickle cell disease. Immunohematology 2006; 22:126-131.
12. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 2001; 38:5-13.
13. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206-213.
14. Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr 2009; 21:15-21.
15. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159:394-404.
16. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42:37-43.
17. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38:30-36.
18. Drasar E, Igbineweka N, Vasavda N, et al. Blood transfusion usage among adults with sickle cell disease-A single institution experience over ten years. Br J Haematol 2011; 152:766-770.
19. Introduction to the HCUP KIDS Inpatient Database: Agency for Healthcare Research and Quality; 2008. Report. http://www.hcup-us.ahrq.gov/db/nation/kid/kid_2006_introduction.jsp
20. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855-1865.
21. McCavit TL, Xuan L, Zhang S, et al. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer 2012; 60:823-827.
22. Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood 2011; 117:5297-5305.
23. Abbas HA, Kahale M, Hosn MA, et al. A review of acute chest syndrome in pediatric sickle cell disease. Pediatr Ann 2013; 42:115-120.
24. Shaz BH, Zimring JC, Demmons DG, et al. Blood donation and blood transfusion: Special considerations for African Americans. Transfus Med Rev 2008; 22:202-214.
25. James AB, Demmons DG, Schreiber GB, et al. Contribution of attitudinal factors to blood donation in African American church attendees. Transfusion 2011; 51:158-165.
26. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617-1621.
27. Shander A, Hofmann A, Gombotz H, et al. Estimating the cost of blood: Past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21:271-289.
28. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000; 96:2369-2372.
29. Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals; 2004. HCUP statistical brief #21. December 2006. Rockville, MD: Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf
30. Sesok-Pizzini DA, Friedman DF, Smith-Whitley K, et al. Transfusion support of patients with sickle cell disease at the Children's Hospital of Philadelphia. Immunohematology 2006; 22:121-125.
31. Hillyer KL, Hare VW, Josephson CD, et al. Partners for life: The transfusion program for patients with sickle cell disease offered at the American Red Cross Blood Services, Southern Region, Atlanta, Georgia. Immunohematology 2006; 22:108-111.
32. Price CL, Johnson MT, Lindsay T, et al. The Sickle Cell Sabbath: A community program increases first-time blood donors in the African American faith community. Transfusion 2009; 49:519-523.
33. Shaz BH, Hillyer CD. Minority donation in the United States: Challenges and needs. Curr Opin Hematol 2010; 17:544-549.
34. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007; 82:255-265.
35. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 2009; 114:4632-4638.
36. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76-79.
37. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009; 52:616-620.
38. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136:501-508.
39. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364:146-156.